Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors.

Journal of translational medicine - 6 Nov 2025

Zhou Muya, Xu Luxia, Hu Jinhua, Chen Wenwen, Hong Jialu, Wang Mufeng, Guo Zhigang

Abstract excerpt

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable success in hematologic malignancies but faces significant challenges in solid tumors due to the immunosuppressive tumor microenvironment (TME). Among these, hypoxia plays a vital role, yet the molecular mediators that link hypoxia to CAR-T dysfunction remain incompletely understood. METHODS: Anti-mesothelin (MSLN) CAR-T cells were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Hypoxia
Share to Cellular Reprogramming

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycolysis

Share to Immunotherapy, Adoptive

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41199316
DOI: 10.1186/s12967-025-07278-5
PMCID: PMC12590754

Genes

PIM3
CD70
MSLN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors.PMID 41199316Read ↗

Palbociclib and Rapamycin pretreatment boosted the persistence and functionality of CAR-T cells in solid tumors through metabolic reprogrammingSemantic proximity Read ↗

Fueling CARs: metabolic strategies to enhance CAR T-cell therapySemantic proximity Read ↗

Polarization of Tumor Cells and Tumor‐Associated Macrophages: Molecular Mechanisms and Therapeutic TargetsSemantic proximity Read ↗

Mitochondrial energy metabolism correlates with an immunosuppressive tumor microenvironment and poor prognosis in esophageal squamous cell carcinomaSemantic proximity Read ↗

Enhanced tumor response to adoptive T cell therapy with PHD2/3-deficient CD8 T cellsSemantic proximity Read ↗

Metabolic reprogramming of the tumor microenvironment to enhance immunotherapySemantic proximity Read ↗

Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cellsSemantic proximity Read ↗

Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockadeSemantic proximity Read ↗

Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironmentSemantic proximity Read ↗

Enhance Memory CD8 <sup>+</sup> T Cell Formation via Downregulation of Hematopoietic Progenitor Kinase 1 and Sustained Mitochondrial FitnessSemantic proximity Read ↗

The epigenetic landscape of tumor-associated macrophages: orchestrating immune evasion in the tumor microenvironmentSemantic proximity Read ↗

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.